Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

ARIAD Pharmaceuticals, Inc. (ARIA - Snapshot Report) recently submitted a Marketing Authorization Application (MAA) for its BCR-ABL inhibitor, ponatinib, to the European Medicines Agency (EMA). ARIAD is looking to get the candidate approved in the EU for use in adult patients suffering from resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

ARIAD had requested accelerated assessment of the MAA for its investigational candidate, which was granted by the Committee for Medicinal Products for Human Use (CHMP).

In June 2012, ARIAD had reported positive data on ponatinib from the PACE trial conducted in patients suffering from CML and Ph+ ALL. Data showed that 54% of chronic-phase CML patients (including 70% patients who had T315I mutation) were successful in achieving a major cytogenetic response (MCyR). ARIAD submitted these data to support its MAA for ponatinib.

Notably, in July this year, ARIAD also applied for US approval of ponatinib for the same indication. We note that ARIAD’s new drug application (NDA) is a rolling submission. The company expects to complete the NDA submission later in the third quarter. The company anticipates potential approval and subsequent launch in the US in the first quarter of 2013.

ARIAD also intends to commercialize ponatinib beyond Europe and the US. The company recently initiated a multi-center phase I/II clinical trial with ponatinib in Japan, the third largest CML market in the world.

The Japanese trial is evaluating ponatinib in patients with CML who have failed treatment with Bristol-Myers Squibb Company’s (BMY - Analyst Report) Sprycel (dasatinib) or Novartis AG’s (NVS - Snapshot Report) Tasigna (nilotinib) or with Ph+ ALL who have failed treatment with tyrosine kinase inhibitors.

Our Recommendation

We currently have a Neutral recommendation on ARIAD. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%